News
CRBP
2.060
-15.40%
-0.375
Corbus Pharmaceuticals Holdings Inc. Stock Sheds 15.4%, Underperforms Peers
Dow Jones · 1d ago
Corbus Pharmaceuticals Holdings Inc. Stock Slides 11.3%, Underperforms Peers
Dow Jones · 2d ago
CSPC Receives $15 Mln Milestone Payment From Corbus For CRB-701 License
NASDAQ · 2d ago
Corbus Pharmaceuticals Holdings Inc. Stock Falls 8.8%, Underperforms Peers
Dow Jones · 3d ago
Corbus Pharmaceuticals Holdings Inc. Stock Falls 10.8%, Underperforms Peers
Dow Jones · 4d ago
Corbus Pharmaceuticals Holdings, Inc. Announces Phase 1b CANYON-1 Trial Data for Obesity Treatment CRB-913
NASDAQ · 5d ago
Analysts Offer Insights on Healthcare Companies: Pro-Dex (PDEX) and Corbus Pharmaceuticals (CRBP)
TipRanks · 5d ago
Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment
Benzinga · 5d ago
Corbus’ CRB-913 shows 5% mean weight loss at 60 mg after 12 weeks
TipRanks · 5d ago
Corbus Pharmaceuticals Reports Positive Oral Obesity Drug Data
TipRanks · 5d ago
Weekly Report: what happened at CRBP last week (1109-1113)?
Weekly Report · 5d ago
Corbus Pharmaceuticals Holdings Inc. Stock Sheds 14.8%, Underperforms Peers
Dow Jones · 11/12 21:33
Thursday Sector Laggards: Agriculture & Farm Products, Biotechnology Stocks
NASDAQ · 11/12 17:26
Corbus Pharmaceuticals Is Maintained at Outperform by Mizuho
Dow Jones · 11/12 13:03
Corbus Pharmaceuticals Price Target Cut to $23.00/Share From $24.00 by Mizuho
Dow Jones · 11/12 13:03
Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $23
Benzinga · 11/12 12:52
Corbus Pharmaceuticals price target lowered to $23 from $24 at Mizuho
TipRanks · 11/12 12:25
Corbus Pharmaceuticals Price Target Cut to $33.00/Share From $36.00 by RBC Capital
Dow Jones · 11/11 15:28
Corbus Pharmaceuticals Is Maintained at Outperform by RBC Capital
Dow Jones · 11/11 15:28
RBC Capital Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $33
Benzinga · 11/11 15:18
More
Webull provides a variety of real-time CRBP stock news. You can receive the latest news about Corbus Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About CRBP
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.